Letter to the Editor: “The role of imaging in the management of progressive glioblastoma. A systematic review and evidence-based clinical practice guideline” [J Neurooncol 2014; 118:435–460]

Langen, Karl‐Josef; Tonn, Joerg C.; Weller, Michael; Galldiks, Norbert

doi:10.1007/s11060-014-1594-z

Cited by 15 publications

(7 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, the Response Assessment in Neuro-Oncology (RANO) working group—an international effort to develop new standardized response criteria for clinical trials in brain tumours—has recommended the additional use of amino acid PET imaging for brain tumour management [ 5 ]. The longest established amino acid tracer 11 C-MET has been replaced in many neuro-oncology centres by the more convenient 18 F-FET, and several thousand 18 F-FET PET scans have been performed in some centres in recent years [ 22 ]. The broad clinical use of 18 F-FET PET requires comparable quantitative parameters, but as yet, the reported cut-off values of different parameters like TBR mean , TBR max , TTP, slope and T vol for tumour grading or differentiation of recurrent tumour from treatment related changes appear to vary among different centres.…”

Section: Discussionmentioning

confidence: 99%

O-(2-[18F]fluoroethyl)-l-tyrosine PET in gliomas: influence of data processing in different centres

et al. 2017

Self Cite

View full text Add to dashboard Cite

BackgroundPET using O-(2-[18F]fluoroethyl)-l-tyrosine (18F-FET) is an established method for brain tumour diagnostics, but data processing varies in different centres. This study analyses the influence of methodological differences between two centres for tumour characterization with 18F-FET PET using the same PET scanner.Methodological differences between centres A and B in the evaluation of 18F-FET PET data were identified for (1) framing of PET dynamic data, (2) data reconstruction, (3) cut-off values for tumour delineation to determine tumour-to-brain ratios (TBR) and tumour volume (Tvol) and (4) ROI definition to determine time activity curves (TACs) in the tumour. Based on the 18F-FET PET data of 40 patients with untreated cerebral gliomas (20 WHO grade II, 10 WHO grade III, 10 WHO grade IV), the effect of different data processing in the two centres on TBRmean, TBRmax, Tvol, time-to-peak (TTP) and slope of the TAC was compared. Further, the effect on tumour grading was evaluated by ROC analysis.ResultsSignificant differences between centres A and B were found especially for TBRmax (2.84 ± 0.99 versus 3.34 ± 1.13; p < 0.001), Tvol (1.14 ± 1.28 versus 1.51 ± 1.44; p < 0.001) and TTP (22.4 ± 8.3 min versus 30.8 ± 6.3 min; p < 0.001) and minor differences for TBRmean and slope. Tumour grading was not influenced by different data processing.ConclusionsVariable data processing of 18F-FET PET in different centres leads to significant differences especially for TBRmax and Tvol. A standardization of data processing and evaluation is needed to make 18F-FET PET comparable between different centres.

show abstract

Section: Discussionmentioning

confidence: 99%

O-(2-[18F]fluoroethyl)-l-tyrosine PET in gliomas: influence of data processing in different centres

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…21 For example, O-(2-[ 18 F]fluoroethyl)-L-tyrosine (FET) was developed in the late 1990s, and its use has grown rapidly, particularly in western Europe, in recent years. [22][23][24] Clinical results in glioma patients with PET using FET appear to be comparable to MET. [25][26][27] In 2014, FET was approved as a medical drug in Europe (Switzerland).…”

Section: Glucose Petmentioning

confidence: 99%

PET imaging in patients with brain metastasis—report of the RANO/PET group

et al. 2019

Self Cite

View full text Add to dashboard Cite

Brain metastases (BM) from extracranial cancer are associated with significant morbidity and mortality. Effective local treatment options are stereotactic radiotherapy, including radiosurgery or fractionated external beam radiotherapy, and surgical resection. The use of systemic treatment for intracranial disease control also is improving. BM diagnosis, treatment planning, and follow-up is most often based on contrast-enhanced magnetic resonance imaging (MRI). However, anatomic imaging modalities including standard MRI have limitations in accurately characterizing posttherapeutic reactive changes and treatment response. Molecular imaging techniques such as positron emission tomography (PET) characterize specific metabolic and cellular features of metastases, potentially providing clinically relevant information supplementing anatomic MRI. Here, the Response Assessment in Neuro-Oncology working group provides recommendations for the use of PET imaging in the clinical management of patients with BM based on evidence from studies validated by histology and/or clinical outcome.

show abstract

“…FDOPA is approved in some European Countries for clinical use, fluciclovine has orphan drug status for brain gliomas at the US FDA [11] and FET is approved for clinical use in brain tumor imaging in Switzerland [12]. In Europe, MET has been replaced in many neurooncology centres by the more convenient FET, and high clinical interest in this method has led to >10,000 FET PET scans being performed in some centres [13].…”

Section: Radiolabelled Amino Acids For Petmentioning

confidence: 99%